AS A RESULT OF REEXAMINATION, IT HAS BEEN DETERMINED THAT:
The patentability of claims 1-2 and 5-6 is confirmed.
Claim 3 is determined to be patentable as amended.
New claims 7-8 are added and determined to be patentable.
Claim 4 was not reexamined.
3. The polynucleotide of claim 2, wherein the heterologous [ DNA sequence of the transposon comprises a ] promoter is operably linked to at least one or more of: i) an open reading frame; ii) a nucleic acid encoding a selectable marker; iii) a nucleic acid encoding a counter-selectable marker; iii) a nucleic acid encoding a regulatory protein; iv) a nucleic acid encoding an inhibitory RNA.
[ 7. The polynucleotide of claim 3, wherein the selectable marker is glutamine synthetase.]
[ 8. The polynucleotide of claim 3, wherein the selectable marker is dihydrofolate reductase.]